ArticleScientific reports2024
Multidrug-resistant conjugative plasmid carrying mphA confers increased antimicrobial resistance in Shigella.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Escalation of CTX-M-producing extensively drug-resistantMicrobiology spectrum · 2026Article
- Genomic and socioeconomic drivers of antimicrobial resistance forecast to 2050.Cell genomics · 2026Article
- Review
- Integration of poliovirus and enteropathogen sewage surveillance in Dhaka Bangladesh: a longitudinal surveillance study, June 2019-June 2020.The Lancet. Microbe · 2026Article
- Shigella flexneri and Shigella sonnei among children under five in Kenya's urban informal settlement.Gut pathogens · 2026Article
- Investigation of the azithromycin resistance rate and related genes involved in this resistance in clinical Shigella species collected from children with diarrhea in Ahvaz, Southwest Iran.Molecular biology reports · 2026Article
- Trimethoprim-Sulfamethoxazole and Azithromycin Resistance inInfection and drug resistance · 2026Article
- Isolation and characterization of lyticFrontiers in cellular and infection microbiology · 2026Article
- Sexually transmitted enteric infections in men who have sex with men.Clinical microbiology reviews · 2025Review
- Circling in on plasmids: benchmarking plasmid detection and reconstruction tools for short-read data from diverse species.Briefings in bioinformatics · 2025Article
- Extended spectrum β-lactamase and integron genes among Shigella flexneri and Shigella sonnei isolated from children with diarrhea in shiraz, Southwest Iran.BMC pediatrics · 2025Article
- Genomic characterization of azithromycin-resistant and extended-spectrum β-lactamase-producingJAC-antimicrobial resistance · 2025Article
- Bacterial Communities and Resistance and Virulence Genes in Hospital and Community Wastewater: Metagenomic Analysis.International journal of molecular sciences · 2025Article
- Prevalence of azithromycin resistance after the COVID-19 era in clinical bacterial isolates from a tertiary care hospital in Gurugram, India.Frontiers in microbiology · 2025Article
- A case of intercurrent shigellosis and rectal gonorrhea in an acutely unwell febrile returned traveler.Therapeutic advances in infectious diseaseArticle
Corrections and comments
- Update of
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Shigellosis remains a common gastrointestinal disease mostly in children < 5 years of age in developing countries. Azithromycin (AZM), a macrolide, is currently the first-line treatment for shigellosis in Bangladesh; ciprofloxacin (CIP) and ceftriaxone (CRO) are also used frequently. We aimed to evaluate the current epidemiology of antimicrobial resistance (AMR) and mechanism(s) of increasing macrolide resistance in Shigella in Bangladesh. A total of 2407 clinical isolates of Shigella from 2009 to 2016 were studied. Over the study period, Shigella sonnei was gradually increasing and become predominant (55%) over Shigella flexneri (36%) by 2016. We used CLSI-guided epidemiological cut-off value (ECV) for AZM in Shigella to set resistance breakpoints (zone-diameter ≤ 15 mm for S. flexneri and ≤ 11 mm for S. sonnei). Between 2009 and 2016, AZM resistance increased from 22% to approximately 60%, CIP resistance increased by 40%, and CRO resistance increased from zero to 15%. The mphA gene was the key macrolide resistance factor in Shigella; a 63MDa conjugative middle-range plasmid was harboring AZM and CRO resistance factors. Our findings show that, especially after 2014, there has been a rapid increase in resistance to the three most effective antibiotics. The rapid spread of macrolide (AZM) resistance genes among Shigella are driven by horizontal gene transfer rather than direct lineage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.